Results 11 to 20 of about 17,861,189 (258)

QALY: Quality Adjusted Life Year

open access: yesMedicine Science, 2012
Nufusun yaslanmasi ve yaslilik donemi hastaliklar ile kronik hastaliklarin one cikmasi verilen saglik hizmetlerinin sadece saglik duzeyi uzerine degil yasam kalitesine etkisinin de onemli bir cikti olarak degerlendirilmesini getirmistir.
Selale Sahin, Selime Toprak, Erdinc Unal
doaj   +2 more sources

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis. [PDF]

open access: yesPharmacoecon Open, 2020
BACKGROUND: No willingness-to-pay (WTP) per quality-adjusted life-year (QALY) value exists for the Kingdom of Saudi Arabia (KSA). OBJECTIVE: The primary objective of this study was to determine the WTP for a QALY in the KSA.
Bazarbashi S   +7 more
europepmc   +2 more sources

Multivariate risk preferences in the quality-adjusted life year model. [PDF]

open access: yesHealth Econ, 2022
International audienceThe interest in multivariate and higher-order risk preferences has increased. A growing body of literature has demonstrated the relevance and impact of these preferences, but for health the evidence is lacking.
Attema AE, Frasch JJ, L'Haridon O.
europepmc   +2 more sources

Consistent valuation of a reduction in mortality risk using values per life, life year, and quality-adjusted life year [PDF]

open access: yes, 2023
The monetary value of a reduction in mortality risk can be accurately characterized using the alternative concepts of value per statistical life (VSL), value per statistical life year (VSLY), and value per quality-adjusted life year (VQALY).
Hammitt, James K., James K. Hammitt
core   +2 more sources

Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis

open access: yesLiver Cancer, 2020
Introduction: Hepatocellular carcinoma (HCC) is the most common form of liver cancer worldwide and carries a poor prognosis. Historically, sorafenib was the only available systemic treatment for advanced HCC.
Christopher Sherrow   +5 more
doaj   +1 more source

Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway [PDF]

open access: yes, 2021
Purpose - Breast cancers detected at screening need less aggressive treatment compared to breast cancers detected due to symptoms. The evidence on the quality of life associated with screen-detected versus symptomatic breast cancer is sparse.
Cairns, John Alexander   +16 more
core   +1 more source

The effect of surfactant type on characteristics, skin penetration and anti-aging effectiveness of transfersomes containing amniotic mesenchymal stem cells metabolite products in UV-aging induced mice

open access: yesDrug Delivery, 2022
Transfersome has been developed to enhance dermal delivery of amniotic mesenchymal stem cell metabolite products (AMSC-MP). AMSC-MP contains many growth factors for managing skin aging, thus improving the quality of an adjusted life year. This study aims
Andang Miatmoko   +9 more
doaj   +1 more source

Methods to Estimate Willingness-to-Pay Per Quality Adjusted Life Year as Cost-Effectiveness Threshold

open access: yesJurnal Manajemen dan Pelayanan Farmasi, 2018
Pharmacoeconomic studies, especially the cost-utility analysis method, require a cost-effectiveness threshold for interpretation of the cost-effectiveness ratios of the study. The cost-effectiveness threshold is determined by each country.
Tri Murti Andayani   +3 more
doaj   +1 more source

"Blanket rules just don't work": Qualitative exploration of the relative value of child and adult quality-adjusted life year (QALY) gains for health technology assessment. [PDF]

open access: yesInt J Technol Assess Health Care
“Blanket rules just don’t work”: Qualitative exploration of the relative value of child and adult Quality Adjusted Life Year (QALY) gains for health technology ...
Sellars M   +4 more
europepmc   +2 more sources

Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies

open access: yesФармакоэкономика, 2018
The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e.
T. S. Teptsova   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy